Straits Times Index
3,277.29 -10.46 (-0.32%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,654.34 +369.80 (+2.14%) FTSE 100
8,129.15 +50.29 (+0.62%) Bitcoin USD
64,463.23 +215.72 (+0.34%) CMC Crypto 200
1,387.21 -9.33 (-0.67%)
Voyager Therapeutics, Inc. (VYGR)
After hours:
| Previous close | 7.57 |
| Open | 7.65 |
| Bid | 7.38 x 100 |
| Ask | 7.44 x 100 |
| Day's range | 7.26 - 7.52 |
| 52-week range | 6.06 - 14.34 |
| Volume | |
| Avg. volume | 647,516 |
| Market cap | 402.91M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 2.50 |
| EPS (TTM) | 2.97 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.78 |
GlobeNewswireVoyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALSLEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene th
- GlobeNewswire
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously a
Simply Wall St.Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Voyager Therapeutics (NASDAQ:VYGR) has had a rough week with its share price down 14%. However, a closer look at its...
